New family medicine residency sites support primary care in Southwestern Ontario - Schulich School of Medicine & Dentistry

Court documents show FSIN knew ISC audit decision before informing members Advocates call for solutions as winter approaches

Helium production is expected to boom in Saskatchewan after a massive new facility began operations Thursday. The purification facility, located west of Regina near Stewart Valley, is expected to produce approximately 73 million cubic feet of helium annually. Saskatchewan’s Energy and Resources Minister Chris Beaudry said work at the site will strengthen Saskatchewan’s position as Canada’s top helium producer. The production will increase provincial exports by more than 40 per cent, the minister said. “Today is another step toward a stronger, more diversified resource economy,” Beaudry told reporters at a news conference. “Around the world, helium demand is growing for medical imaging, aerospace, advanced manufacturing and the technologies that are shaping our future.”North American Helium, a gas supplier headquartered in Calgary, is operating the facility. In a news release issued Sept. 22, the company claimed an independent evaluator said there are 1.1 billion cubic feet of helium reserves at the Stewart Valley site. Story continues below advertisement

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.